Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Dietrich Gulba is currently managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This lone action constitutes the entire active prosecution workload for the entity at the USPTO. The focus on 1 pending office action suggests that Dietrich Gulba is currently prioritizing a specific technical development within the broader research and development efforts.
The examination of this application is being handled by 1 distinct examiner, MAEWALL, SNIGDHA. As the only official assigned to the portfolio, MAEWALL, SNIGDHA is also the busiest examiner with 1 pending office action under her review. This prosecution is taking place within 1 distinct art unit, which further emphasizes the concentrated nature of the current patent activities in the Biotechnology & Pharmaceuticals sector.
For a practitioner, the presence of 1 distinct examiner and 1 distinct art unit for the 1 pending office action simplifies the interaction with the USPTO. There is no requirement to manage different examiner styles or art unit interpretations, as all activity is localized. This structure benefits from a direct line of communication with MAEWALL, SNIGDHA, ensuring a consistent prosecution path for the 1 pending office action without the complexity of a distributed portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MAEWALL, SNIGDHA | 1 | 58.8% | +10.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18285746 | USE OF ANTI-CLOTTING COMPOUNDS AS RODENTICIDES | MAEWALL, SNIGDHA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18285746 | USE OF ANTI-CLOTTING COMPOUNDS AS RODENTICIDES | MAEWALL, SNIGDHA | — |
| Art Unit | Apps |
|---|---|
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18285746 | USE OF ANTI-CLOTTING COMPOUNDS AS RODENTICIDES | MAEWALL, SNIGDHA | 1612 | §102§103§112 | Non-Final OA | — | Pending | Oct 05, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDietrich Gulba has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Snigdha Maewall has the most, with 1 of Dietrich Gulba's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
